PharmaTher's KETARx Wins FDA Approval For Surgical Pain Management Usage, Stock Surges

(RTTNews) - PharmaTher Holdings Ltd. (PHRRF.PK), Monday announced that the U.S. Food and Drug Administration has approved KETARx for its indicated uses in surgical pain management.

The approval strategically positions the company to contribute to the psychedelic pharmaceutical revolution by leveraging its commercial and clinical initiatives with ketamine towards mental health, neurological, and pain disorders. With the ketamine market expected to reach $3.42 billion by 2034, this approval indicates the potential growth of KETARx across diverse therapeutic areas within the company's product pipeline.

Currently, PharmaTher's stock is surging 38.89 percent, to $0.50 on the OTC Markets.